

# Tigecycline (mesylate)

Catalog No: tcsc1878



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg



## Specifications

**CAS No:**

1135871-27-0

**Formula:**

$C_{30}H_{43}N_5O_{11}S$

**Pathway:**

Anti-infection

**Target:**

Bacterial

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

GAR-936 mesylate

**Observed Molecular Weight:**

681.75

**Product Description**

Tigecycline mesylate a first-in-class, broad spectrum antibiotic with activity against antibiotic-resistant organisms.

Target: Antibacterial


Tigecycline mesylate is active against a broad range of gram-negative and gram-positive bacterial species including clinically important multidrug-resistant nosocomial and community-acquired bacterial pathogens. Tigecycline mesylate has been shown to inhibit the translation elongation step by binding to the ribosome 30S subunit and preventing aminoacylated tRNAs to accommodate in the ribosomal A site [1]. Tigecycline mesylate has also been found to be effective for the treatment of community- as well as hospital-acquired and ventilator-associated pneumonia and bacteremia, sepsis with shock and urinary tract infections. Tigecycline mesylate appears to be a valuable treatment option for the management of superbugs, especially where conventional therapy has failed [2].

Fifteen patients received tigecycline mesylate for 16 episodes of CPKP infection. The main infections were pneumonia (31%), urinary tract infection (31%), peritonitis (20%), catheter-related bacteraemia (12%), and meningitis (6%). Most infections were complicated with severe sepsis (44%), septic shock (12%), and/or bacteraemia (19%). The daily maintenance dose of tigecycline mesylate was 200 mg in 10 episodes and 100 mg in 6 episodes. The overall 30-day mortality rate was 25%. Univariate analysis showed that mortality was significantly associated (p

Clinical indications: Acinetobacter infection; Bacterial infection; Bacterial pneumonia; Bacterial skin infection; Bacteroides fragilis infection; Bacteroides infection; Citrobacter infection; Clostridiaceae infection; Clostridium difficile infection; Clostridium infection; Enterobacter infection

FDA Approved Date: June 17, 2005

Toxicity: nausea; vomiting; diarrhea; local IV-site reaction; infection; fever; headache



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!